Michael L. Meyers

Insider Reports History

Location
Waltham, MA
Signature
/s/ Nathan N. McConarty, attorney-in-fact
Transaction view
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Holdings reported by Michael L. Meyers:

Form 4 holding SVP, Chief Medical Officer

Syndax Pharmaceuticals Inc

Security class
Stock Options (Right to buy)
Shares / value
17,350
Estimated value
$448,388
Report date
02 Feb 2022
Price
$25.84
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding SVP, Chief Medical Officer

Syndax Pharmaceuticals Inc

Security class
Common Stock
Shares / value
23,280
Estimated value
$425,212
Report date
31 Jan 2022
Price
$18.27
Ownership
Direct

Insider Reports Filed by Michael L. Meyers

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .